Beo Therapeutics ApS: Financial statements 2024
CVR: 39880377
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Beo Therapeutics ApS (CVR 39880377) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -5,000 and a net result of DKK -4,910 compared with DKK 0 the year before. Equity in the 2024 report amounted to DKK 35,090. The solvency ratio was 1%.
- Gross Profit
- DKK -5,000
- Profit/Loss
- DKK -4,910
- Equity
- DKK 35,090
- Total Assets
- DKK 3,640,558
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -5K | -5K | 35K | - |
| 2023 | - | - | 0 | 40K | - |
| 2022 | - | - | 0 | 40K | - |
| 2021 | - | - | 418 | 40K | - |
| 2020 | - | - | 0 | 67K | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Beo Therapeutics ApS has published its annual report for 2023. The net result was DKK 0.
About Beo Therapeutics ApS
Beo Therapeutics ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2018. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Beo Therapeutics IVS. The management consists of Rikke Christina Nielsen. The company is owned by Rikke Christina Nielsen. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK 0 and a net result of DKK 4,985 compared with DKK -4,910 the year before. Equity in the 2025 report amounted to DKK 40,075.